Autolus Therapeutics annual depreciation and amortization
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Autolus Therapeutics Depreciation & Amortization Growth & History (AUTL)
Autolus Therapeutics's depreciation and amortization was $8.3M for fiscal 2025.
View full Autolus Therapeutics company overviewAutolus Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.3M | $742,000 | +9.82% |
| 2024 | 2024-12-31 | $7.6M | $989,000 | +15.06% |
| 2023 | 2023-12-31 | $6.6M | −$857,000 | −11.55% |
| 2022 | 2022-12-31 | $7.4M | −$1.0M | −12.25% |
| 2021 | 2021-12-31 | $8.5M | $2.8M | +49.49% |
| 2020 | 2020-12-31 | $5.7M | $1.0M | +22.71% |
| 2019 | 2019-12-31 | $4.6M | — | — |
| 2018 | 2018-09-30 | $1.7M | $700,000 | +69.38% |
| 2017 | 2017-09-30 | $1.0M | $531,000 | +111.09% |
| 2016 | 2016-09-30 | $478,000 | — | — |
Autolus Therapeutics quarterly depreciation and amortization
Q2.18
Q4.18
Q1.19
Q2.19
Q3.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.2M | $78,000 | +3.74% |
| Q1 2026 | 2026-03-31 | $2.2M | $217,000 | +10.89% |
| Q4 2025 | 2025-12-31 | −$137,000 | — | — |
| Q3 2025 | 2025-09-30 | $2.1M | $141,000 | +7.28% |
| Q2 2025 | 2025-06-30 | $2.1M | $188,000 | +9.92% |
| Q1 2025 | 2025-03-31 | $2.0M | $186,000 | +10.30% |
| Q3 2024 | 2024-09-30 | $1.9M | $559,000 | +40.54% |
| Q2 2024 | 2024-06-30 | $1.9M | $383,000 | +25.33% |
| Q1 2024 | 2024-03-31 | $1.8M | −$93,000 | −4.90% |
| Q3 2023 | 2023-09-30 | $1.4M | −$421,000 | −23.39% |
| Q2 2023 | 2023-06-30 | $1.5M | — | — |
| Q1 2023 | 2023-03-31 | $1.9M | — | — |
| Q3 2022 | 2022-09-30 | $1.8M | — | — |
| Q1 2021 | 2021-03-31 | $1.7M | $401,000 | +31.80% |
| Q3 2020 | 2020-09-30 | $1.5M | $326,000 | +28.55% |
| Q2 2020 | 2020-06-30 | $1.3M | $726,000 | +134.20% |
| Q1 2020 | 2020-03-31 | $1.3M | −$378,000 | −23.06% |
| Q3 2019 · Sep 30 | 2019-09-30 | $1.1M | $723,000 | +172.55% |
| Q3 2019 · Jun 30 | 2019-06-30 | $541,000 | $41,000 | +8.20% |
| Q2 2019 | 2019-03-31 | $1.6M | — | — |
| Q1 2019 | 2018-12-31 | $645,000 | — | — |
| Q4 2018 | 2018-09-30 | $419,000 | — | — |
| Q2 2018 | 2018-06-30 | $500,000 | — | — |
Autolus Therapeutics depreciation and amortization trends
Over the last five fiscal years, Autolus Therapeutics's depreciation and amortization increased from $5.7M to $8.3M, a change of $2.6M. The latest reported quarter, Q2 2026, shows $2.2M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Autolus Therapeutics source filings ↗